Lorazepam injection vials recalled nationwide for manufacturing specification failures
Hikma Pharmaceuticals is recalling approximately 4.7 million vials of Lorazepam injection nationwide after finding out-of-specification related compounds during quality testing. The affected lots expire between June and August 2023.
- Product
- LORAZEPAM — LORAZEPAM (LORAZEPAM)
- Category
- Drug
- Distribution
- Distributed nationwide